PROVIDENCE – Lyora Therapeutics, a Providence-based biotech company specializing in the treatment of hereditary retinal diseases, has officially launched publicly after operating in stealth for the past year. Lyora’s portfolio currently includes three treatments under development for genetic retinal diseases that cause vision loss and potential blindness for retinitis pigmentosa, Usher syndrome and Leber Congenital Amaurosis, according to the firm’s
Already a Subscriber? Log in
To Continue Reading This Article
Become a Providence Business News subscriber and get immediate access to all of our premier content and much more.Learn More and Become a Subscriber
- Critical RI business news and analysis updated daily.
- 1 year of print (26 issues).
- Unlimited access to all subscriber only content on our website, on any device.
- Free email alerts.
- Annual Book of Lists Print Edition.
- All special issues produced during subscription term.
Click Here to purchase a paywall bypass link for this article
PBN Branded Content
Beyond Cash Donations: How New Forms of Giving Are Transforming Not-for-Profit Accounting
Evolving Funding Landscape for Not-for-Profits Not-for-profit organizations are being asked to do more with less,…
Learn More
